Age-Related Macular Degeneration Research and Drug Development

Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness among individuals aged 50 years and older. It is a multifactorial disease influenced by both genetic and environmental factors. AMD primarily affects the macula, the central part of the retina responsible for sharp, central vision. As the population ages, the prevalence of AMD is expected to rise, necessitating the development of effective treatments and therapies.

At CD BioSciences, we understand the significance of AMD research and drug development in combating this debilitating condition. With our extensive experience and technologies, we provide a wide range of research and development (R&D) services tailored specifically for AMD.

1-7-age-related-macular-degeneration-research-and-drug-development-1

Pathogenic Mechanism Analysis Services for AMD

We offer analysis services to elucidate the complex pathways and molecular interactions involved in AMD progression, including but not limited to the following.

Analysis of extracellular matrix (ECM). We specialize in analyzing ECM, providing insights into the changes occurring in the ECM composition and structure during AMD progression. We provide various techniques such as immunohistochemistry, proteomics, and gene expression analysis to evaluate ECM components, including collagen, elastin, fibronectin, and proteoglycans.
Assessment of oxidative stress. Oxidative stress plays an important role in aging diseases like AMD. We provide advanced analysis services to assess oxidative stress levels and evaluate its impact on retinal cells and tissues. Our team employs fluorescent probes and enzymatic assays, to measure oxidative stress markers accurately, such as ROS production, lipid peroxidation, and protein oxidation.
Analysis of lipid metabolism. We employ advanced lipidomics techniques to analyze lipid profiles and identify changes in lipid composition, including the levels of specific lipids and lipid metabolites. By studying the metabolism and distribution of lipids within the retina, we can help clients uncover key lipid-related pathways involved in AMD pathogenesis.

Biomarker Identification Services for AMD

We specialize in biomarker identification services for AMD, utilizing cutting-edge technologies to identify and validate potential biomarkers associated with the disease. Through a combination of high-throughput screening, bioinformatics analysis, and validation studies, we identify biomarkers that can aid in the early diagnosis and monitoring of AMD. Our expertise in biomarker discovery enables us to develop reliable tools and assays for clinical and preclinical studies, facilitating efficient drug development processes.

Disease Model Customization Services for AMD

We offer disease model customization services tailored specifically for AMD, enabling our clients to mimic the disease conditions and evaluate drug candidates in a preclinical setting. Our team of experts utilizes cell culture techniques and animal models to create physiologically relevant models of AMD. Our models allow for the evaluation of drug efficacy, toxicity, and pharmacokinetics, providing valuable data for the development of safe and effective treatments.

Drug Discovery and Development Services for AMD

CD BioSciences is dedicated to drug discovery and development for AMD. Our integrated services cover all stages of the drug development process, from target identification and lead optimization to preclinical studies. Using our expertise in medicinal chemistry and pharmacology, we facilitate the identification and optimization of lead compounds with the potential to treat AMD. Our preclinical studies involve comprehensive efficacy and safety assessments using relevant disease models. We also assess the efficacy of potential therapeutics in halting disease progression, preserving visual function, and reducing the risk of complications.

Healthcare R&D Services for AMD

In addition to drug development, CD BioSciences offers healthcare product research and development services for AMD. Certain nutrients, such as vitamins C and E, lutein, zeaxanthin, and omega-3 fatty acids like DHA and EPA, have been linked to reduced risk or slower progression of the disease. Our team of experts collaborates closely with clients to develop customized nutritional supplement formulations that address the unique requirements of individuals with AMD. We also consider the bioavailability and optimal dosages of these nutrients to ensure maximum efficacy.

At CD BioSciences, we are committed to advancing AMD research and drug development through our comprehensive suite of R&D services. If you are interested in our services, please feel free to contact us or make an online inquiry.

Reference

Vyawahare H, Shinde P. Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment. Cureus, 2022, 14 (9), e29583.